Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tontanai Numbenjapon is active.

Publication


Featured researches published by Tontanai Numbenjapon.


Clinical Cancer Research | 2009

Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

Tontanai Numbenjapon; Jianyi Wang; David Colcher; Thomas Schluep; Mark E. Davis; Julienne Duringer; Leo Kretzner; Yun Yen; Stephen J. Forman; Andrew Raubitschek

Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11. Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated. Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice. Conclusions: The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.


Leukemia | 2006

Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells [4]

Tontanai Numbenjapon; Lisa Marie Serrano; Harjeet Singh; Claudia M. Kowolik; Simon Olivares; Nancy Gonzalez; Wen-Chung Chang; S. J. Forman; Michael C. Jensen; Laurence J.N. Cooper

Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells


Hematological Oncology | 2018

Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand

Tanin Intragumtornchai; Udomsak Bunworasate; Kitsada Wudhikarn; Arnuparp Lekhakula; Jakrawadi Julamanee; Kanchana Chansung; Chittima Sirijerachai; Lalita Norasetthada; Weerasak Nawarawong; Archrob Khuhapinant; Noppadol Siritanaratanakul; Tontanai Numbenjapon; Kannadit Prayongratana; Suporn Chuncharunee; Pimjai Niparuck; Tawatchai Suwanban; Nongluk Kanitsap; Somchai Wongkhantee; Rutchanid Pornvipavee; Peerapon Wong; Nisa Makruasi; Pongsak Wannakrairot; Thamathorn Assanasen; Sanya Sukpanichnant; Paisarn Boonsakan; Wasana Kanoksil; Charin Ya-in; Kanita Kayasut; Winyu Mitranun; Naree Warnnissorn

Systemic reports on the descriptive epidemiology of non‐Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi‐institutional registry was conducted to compare the histopathology, clinical features, and survival of Thai adult patients with NHL using large registries, especially those from Far East Asia (FEA). Using a web‐based registry system, 13 major medical centers from the 4 geographic regions of Thailand prospectively collected, from 2007 to 2014, the diagnostic pathology, according to the World Health Organization classification, 2008, clinical features and survival of 4056 patients who were newly diagnosed with NHL. The median age of the patients was 56 years (range, 16‐99 years). The male‐to‐female ratio was 1.3:1. From the total of 4056 patients, T/NK‐cell lymphoma (TNKCL) accounted for 12.6% of cases, and 5.1% had human immunodeficiency virus–associated lymphoma. The four leading histological subtypes were diffuse large B‐cell lymphoma, not otherwise specified (58.1%); follicular lymphoma (5.6%); extranodal mucosa‐associated lymphoid tissue lymphoma (5.2%); and peripheral T‐cell lymphoma, not otherwise specified (4.0%). With a median follow‐up duration of 46.1 months, the median overall survival of B‐cell NHL was significantly longer than that of patients with TNKCL (76.5 vs 28.8 months, P = .0001). Compared to FEA, the Thai registry had an approximately one‐half lower relative frequency of TNKCL; the prevalence of extranodal mucosa‐associated lymphoid tissue lymphoma was much lower than in Korea, and the frequency of extranodal TNKCL, nasal type, was strikingly low compared to China. It is concluded that while the median age of Thai patients with NHL was approximately a decade younger than for Caucasians, the long‐term survival rates for most histological subtypes were comparable. While the histological distribution generally complied with the characteristic Asian features, some differences from FEA were observed.


Blood | 2006

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy

Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel H. Kim; David D. Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J. Forman; Michael C. Jensen; Laurence J.N. Cooper


Experimental Hematology | 2007

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells

Tontanai Numbenjapon; Lisa Marie Serrano; Wen-Chung Chang; Stephen J. Forman; Michael C. Jensen; Laurence J.N. Cooper


Annals of Hematology | 2017

Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry

Kitsada Wudhikarn; Udomsak Bunworasate; Jakrawadee Julamanee; Arnuparp Lekhakula; Suporn Chuncharunee; Pimjai Niparuck; Supachai Ekwattanakit; Archrob Khuhapinant; Lalita Norasetthada; Weerasak Nawarawong; Nisa Makruasi; Nonglak Kanitsap; Chittima Sirijerachai; Kanchana Chansung; Peerapon Wong; Tontanai Numbenjapon; Kannadit Prayongratana; Tawatchai Suwanban; Somchai Wongkhantee; Pannee Praditsuktavorn; Tanin Intragumtornchai


Journal of Hematology and Transfusion Medicine (วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต) | 2016

Successful Treatment of Thymoma-related Aplastic Anemia with Cyclosporin A: A case report and review of the literature

Manassamon Hirunmassuwan; Tontanai Numbenjapon; Pongrat Niramitmahapanya; Tanaphon Sinhaseni; Kannadit Prayongratana; Apichai Leelasiri; Chantrapa Sriswasdi


Blood | 2016

A Matched-Pair Analysis of EPOCH Versus CHOP As Frontline Therapy for Nodal Peripheral T-Cell Lymphoma, Excluding ALK-Positive Anaplastic T-Cell Lymphoma: A Multicenter Experience in Thailand

Lalita Norasetthada; Weerasak Nawarawong; Udomsak Bunworasate; Kitsada Wudhikarn; Arnuparp Lekhakula; Jakrawadee Julamanee; Tontanai Numbenjapon; Kannadit Prayongratana; Chittima Sirijerachai; Kanchana Chansung; Nisa Makruasi; Somchai Wongkhantee; Pannee Praditsuktavorn; Tanin Intragumtornchai


Blood | 2016

Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience

Kanchana Chansung; Chittima Sirijerachai; Arnuparp Lekhakula; Pongtep Viboonjuntra; Pimjai Niparuck; Teeraya Pauvilai; Tontanai Numbenjapon; Udomsak Bunworasate; Weerasak Nawarawong; Adisak Tantiworawit; Tawatchai Suwanban


Blood | 2015

Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand

Nonglak Kanitsap; Naree Wannissorn; Arnuparp Lekhakula; Jakrawadee Julamanee; Archrob Khuhapinant; Chittima Sirijerachai; Kanchana Chansung; Lalita Norasetthada; Weerasak Nawarawong; Suporn Chuncharunee; Pimjai Niparuck; Kitsada Wudhikarn; Udomsak Bunworasate; Tontanai Numbenjapon; Kannadit Prayongratana; Somchai Wongkhantee; Peerapon Wong; Tawatchai Suwanban; Nisa Makruasi; Tanin Intragumtornchai

Collaboration


Dive into the Tontanai Numbenjapon's collaboration.

Top Co-Authors

Avatar

Arnuparp Lekhakula

Prince of Songkla University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nisa Makruasi

Srinakharinwirot University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jakrawadee Julamanee

Prince of Songkla University

View shared research outputs
Researchain Logo
Decentralizing Knowledge